Press Releases Keyword Search Year None20212020201920182017 May 3, 2021 FibroGen to Report First Quarter 2021 Financial Results April 28, 2021 FibroGen to Present at Upcoming Investor Conference April 15, 2021 FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy April 12, 2021 FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy April 6, 2021 FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021 April 6, 2021 FibroGen Provides Additional Information on Roxadustat March 16, 2021 FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy March 1, 2021 FibroGen Provides Regulatory Update on Roxadustat March 1, 2021 FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results February 18, 2021 FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results February 12, 2021 FibroGen to Present at Upcoming Investor Conferences
